As the prevalence of multidrug-resistant and extensively drug-resistant tuberculosis strains continues to rise, so does the need to develop accurate and rapid molecular tests to complement time-consuming growth-based drug susceptibility testing. Performance of molecular methods relies on the association of specific mutations with phenotypic drug resistance and while considerable progress has been made for resistance detection of first-line antituberculosis drugs, rapid detection of resistance for secondline drugs lags behind. The rrs A1401G allele is considered a strong predictor of cross-resistance between the three second-line injectable drugs, capreomycin (CAP), kanamycin, and amikacin. However, discordance is often observed between the rrs A1401G mutation and CAP resistance, with up to 40% of rrs A1401G mutants being classified as CAP susceptible. We measured the MICs to CAP in 53 clinical isolates harboring the rrs A1401G mutation and found that the CAP MICs ranged from 8 g/ml to 40 g/ml. These results were drastically different from engineered A1401G mutants generated in isogenic Mycobacterium tuberculosis, which exclusively exhibited high-level CAP MICs of 40 g/ml. These data support the results of prior studies, which suggest that the critical concentration of CAP (10 g/ml) used to determine resistance by indirect agar proportion may be too high to detect all CAP-resistant strains and suggest that a larger percentage of resistant isolates could be identified by lowering the critical concentration. These data also suggest that differences in resistance levels among clinical isolates are possibly due to second site or compensatory mutations located elsewhere in the genome.
G
lobal tuberculosis (TB) control efforts are severely complicated by the emergence and spread of multidrug-resistant (MDR) TB, as evidenced by the half million new MDR TB cases reported by the World Health Organization (WHO) last year (1) . MDR TB is defined as Mycobacterium tuberculosis resistant to two of the most potent first-line antituberculosis agents, rifampin (RIF) and isoniazid (INH) (1) . Treatment requires the administration of second-line antibiotics that are more expensive, can lead to more adverse side effects, and increase treatment duration time relative to first-line drugs (1, 2) . Unfortunately, inadequate treatment of MDR TB and the misuse of second-line antibiotics have contributed to the emergence of extensively drug-resistant (XDR) TB strains, defined by WHO as multidrug resistant with additional resistance to any fluoroquinolone and at least one of the injectable aminoglycoside agents kanamycin (KAN), amikacin (AMK), or capreomycin (CAP) (1) .
Rapid and reliable diagnosis of antibiotic resistance is critical in controlling the spread of drug-resistant TB. Laboratories are increasingly adopting rapid molecular methods to identify mutations associated with resistance as a complement to the more time-consuming growth-based methods (3, 4) . Though molecular methods can increase specificity and drastically reduce delay in the diagnosis of drug-resistant TB compared to growth-based drug susceptibility testing (DST), these methods rely heavily upon basic research to identify and associate specific mutations with drug resistance. A remaining challenge for transitioning to molecular drug resistance detection for TB patients includes establishing correlations between phenotypic resistance and genetic mutations that confer resistance to the second-line antibiotics imperative for treating drug-resistant TB.
Injectable antibiotics such as the aminoglycosides KAN and AMK and the cyclic peptide CAP are key second-line drugs for treating cases of MDR TB (1) . These antibiotics inhibit protein translation by binding to the 16S rRNA (5, 6) . As all three drugs share the same molecular target and bind to a similar location on the ribosome, cross-resistance is frequently observed (3, (7) (8) (9) . Cross-resistance is highly associated with mutations mapping to the 16S rRNA (rrs) sequence, most notably, the A1401G, C1402T, and G1484T mutations (7, (10) (11) (12) . Studies on the contribution of each mutation to specific cross-resistance patterns are variable. Of particular concern is the discordant relationship between the most common rrs mutation, A1401G, and CAP resistance, as this mutation is often found in clinical isolates determined to be CAP susceptible by the agar proportion method of DST (3, 7, 9, (12) (13) (14) (15) (16) (17) (18) . Despite these discrepancies, the presence of the A1401G allele is considered a strong predictor of cross-resistance to all three injectable second-line drugs (4, 17, 19) .
A possible explanation for these discrepancies suggested by several recent studies is that the critical concentration of CAP (10 g/ml) (13) currently used for DST may be too high to accurately detect resistance in clinical isolates whose MIC of CAP is above wild-type (WT) levels but below the critical concentration (15, 17, 18, 20) . Another factor to consider is that the genetic background of an isolate could also influence CAP resistance levels, as has been previously suggested for variable isoniazid resistance levels in clinical isolates from the Beijing lineage (21) . Alternatively, exposure to different host factors or drugs during treatment could lead to compensatory or second-site mutations in the genome that indirectly affect phenotypic resistance, consequently affecting the results of drug susceptibility testing. To investigate these possibilities, we used mycobacteriophage-based recombineering (recombination-mediated genetic engineering) to generate rrs mutants in clean genetic backgrounds across several mycobacterial lineages and compared their resistance profiles to wild-type clinical isolates and those harboring rrs mutations.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Mycobacterium tuberculosis strains H37Rv, CDC1551, Beijing F2, and clinical isolates were grown in Middlebrook 7H9 broth (7H9) supplemented with 10% (vol/vol) albumin-dextrose-catalase (ADC) enrichment (Difco Laboratories) and 0.05% (vol/vol) Tween 80 (Sigma-Aldrich) or on Middlebrook 7H10 agar (7H10) plates supplemented with 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC) enrichment (Difco Laboratories) at 37°C. The media were supplemented with hygromycin (HYG) (75 g/ml), KAN (25 g/ml), AMK (4 g/ml), CAP (10 g/ml), or sucrose (10%) when needed. Antibiotics were purchased from Sigma-Aldrich. Clinical isolates that were previously identified as being either pansusceptible or harboring a rrs mutation were selected from the culture collection at the Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination at the Centers for Disease Control and Prevention, Atlanta, GA, USA (3).
Generation of engineered mutant strains. The nonintegrating plasmid pJV128 (a gift from Graham F. Hatfull, University of Pittsburgh) is a derivative of the recombineering plasmid pJV75-Amber (22) that contains the aph KAN resistance gene, a nonfunctional HYG resistance gene with two adjacent nonsense codons in the open reading frame, the Che9c mycobacteriophage recombinase gp61 under the control of an acetamideinducible promoter, and the counterselectable marker sacB. Single-colony picks of M. tuberculosis strains H37Rv, CDC1551, and Beijing F2 were grown in 100 ml of 7H9 to an optical density at 600 nm (OD 600 ) of 1.0 and made electrocompetent with four washes in prewarmed 10% glycerol. Each strain was transformed with 100 ng of pJV128, allowed to recover for 24 h in 7H9 broth, and plated on 7H10 medium containing KAN (25 g/ml) for 28 days at 37°C. KAN-resistant colonies were streaked for isolation on 7H10 plates containing KAN, and the presence of pJV128 was confirmed by PCR using oligonucleotides complementary to the sacB and aph genes. Strains containing pJV128 were grown to log phase (OD 600 of ϳ0.8), washed in 7H9 broth containing 0.2% succinate (7H9-succinate), and diluted to an OD 600 of 0.05 in 7H9-succinate. When strains reached an OD 600 of 0.4, expression of gp61 was induced with the addition of 0.2% acetamide for 24 h. Induced cells were then made electrocompetent with four washes in prewarmed 10% glycerol. Each strain was transformed with either 100 ng of the single-stranded oligonucleotide JCV198 alone (22) (which corrects the nonfunctional HYG gene in pJV128) or JCV198 in combination with 500 ng of a 63-bp single-stranded oligonucleotide designed to introduce one of three point mutations into a 1,400-bp region of rrs (A1401G, C1402T, and G1484T) ( Table 1 ). All oligonucleotides were obtained from Integrated DNA Technologies. Electroporations were recovered for 72 h in 7H9 broth at 37°C and then plated on 7H10 medium containing HYG. After 28 days, HYG-resistant colonies were patch plated onto 7H10 medium and 7H10 medium containing AMK or KAN. Isolates that tested positive for drug resistance were picked from the 7H10 patch plates without drug, and the 1,400-bp region of the rrs gene was amplified by PCR and sequenced as previously described (3). Isolates identified as rrs mutants were grown in 7H9 to an OD 600 of 1.0, serially diluted (1:10), and plated on 7H10 plates containing 10% sucrose to cure the strains of pJV128. After 28 days at 37°C, sucrose-resistant colonies were inoculated into 7H9 broth, and the loss of pJV128 was confirmed by PCR of the sacB and aph genes. To ensure equivalent manipulation of strains in this study, pJV128 was introduced into the H37Rv, CDC1551, and Beijing F2 parental strains and subsequently resolved by plating isolates on 7H10 plates containing 10% sucrose.
Drug susceptibility testing. The susceptibilities to KAN, AMK, and CAP were determined by the indirect agar proportion method as defined by the Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS) (13) on 7H10 plates containing KAN at 0.5, 1, 2, 3, 4, 5, 10, 20, 40, 80, 100, and 160 g/ml, AMK at 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 100, and 128 g/ml, and CAP at 1, 2, 4, 6, 8, 10, 14, 20, 40, 80, 160, and 320 g/ml. The MIC was defined as the lowest concentration of drug resulting in growth of Յ1% of the initial inoculum after 4 weeks of incubation at 37°C.
Growth curves. Three independent colonies of the wild-type (WT) M. tuberculosis strains H37Rv, CDC1551, and Beijing F2 along with three replicates of the independently isolated recombinant strains (each harboring an A1401G, C1402T, or G1484T rrs mutation in the H37Rv, CDC1551, and Beijing F2 backgrounds) were grown in 7H9 broth at 37°C until reaching an OD 600 between 0.8 and 1.0. Each isolate was diluted in 5 ml of fresh 7H9 broth to an initial OD 600 of 0.05 and incubated at 37°C on a rolling drum to provide aeration, and growth was measured by examination of the OD 600 every 24 h for 10 days. These procedures were performed for each strain in three replicate experiments.
RESULTS
rrs genotypes in cross-resistant clinical isolates. We selected 74 isolates from our collection that were previously genetically and phenotypically characterized (3). We selected only rrs mutant strains that harbored WT tlyA and eis genes, since mutations in these loci have been implicated in resistance to CAP and KAN. These mutant strains included 53 isolates that harbored the rrs A1401G mutation and one isolate each that harbored the C1402T and G1484T mutation. The remaining 19 isolates were WT for all three loci (rrs, eis, and tlyA) and included 10 pansusceptible, 8 MDR (of which 3 were pre-XDR) isolates, and 1 monoresistant (CAP-resistant) strain (3). Resistance was previously defined as growth on Middlebrook 7H10 agar using standard definitions as stated by CLSI; growth on 5 g/ml KAN, 4 g/ml AMK, or 10 g/ml CAP (13) . The single isolate in the collection harboring a C1402T mutation displayed resistance to KAN and CAP but was susceptible to AMK, and the isolate with a G1484T mutation was cross-resistant to all three antibiotics (Table 2) . One clinical isolate was also cross-resistant to all three drugs but maintained a WT genotype in all loci examined for resistance-associated mutations (eis, tlyA, and rrs). Two clinical isolates that were resistant to CAP but susceptible to KAN and AMK also had WT genotypes ( Table  2 ). All of the A1401G mutants were resistant to both KAN and AMK. However, only 45 of the 53 isolates (85%) were also crossresistant to CAP, while the other 8 isolates (15%) remained CAP susceptible (Table 2) .
Clinical isolates harboring an rrs A1401G mutation display a range of capreomycin MICs. In this study, 15% of isolates that were identified as genetically resistant to CAP are phenotypically susceptible by the standard agar-based DST method (Table 2) .
To more closely investigate the relationship between the rrs A1401G mutation and CAP resistance, we determined the MICs for each clinical isolate harboring this mutation (Table 3) . Each isolate was highly resistant to KAN (MIC of Ͼ80 g/ml) and AMK (MIC of Ͼ64 g/ml). However, we observed a range of resistance levels to CAP. The majority (45/53 [85%]) of clinical isolates with the rrs A1401G mutation had MICs that ranged from 14 to 40 g/ml (Table 3) . Eight of the 53 (15%) isolates harboring the A1401G mutation exhibited MICs of 8 g/ml, which is below the critical concentration (10 g/ml) for agar proportion and considered susceptible to CAP (Table 3 ) (13) . The single clinical isolates harboring a C1402T or G1484T mutation were also investigated, and the isolate with the C1402T mutation had an MIC of 40 g/ ml, while the isolate with the G1484T mutation exhibited very high-level resistance to CAP (MIC of Ͼ320 g/ml) ( Table 3) . Three of 19 isolates with WT rrs genes exhibited MICs at 20 g/ml or 40 g/ml and were considered CAP resistant, while the remaining 16 isolates had MICs of 2 to 8 g/ml and were considered susceptible to CAP based on current phenotypic testing methods (Table 3) . Additionally, as the spoligotypes of each clinical isolate in this study were determined in a previous study (3), we could analyze whether the variation in CAP MICs is linked to a particular M. tuberculosis lineage. Interestingly, we observed a larger variation in CAP MICs in clinical isolates belonging to the Beijing lineage than in the Euro-American lineage (Table 3) .
Cross-resistance of injectable antibiotics in clean genetic backgrounds. We used recombineering to generate rrs A1401G mutations in the H37Rv laboratory strain of M. tuberculosis and two representative strains of circulating M. tuberculosis lineages, CDC1551 (Euro-American) and Beijing F2. By agar proportion, each parental strain was pansusceptible to all three of the injectable antibiotics (Table 4) . Interestingly, all of the engineered A1401G mutants were completely cross-resistant to KAN, AMK, and CAP (Table 4) . Moreover, all of the A1401G mutants displayed identical MIC patterns, regardless of parental genetic background, with MICs of Ͼ160 g/ml for KAN, Ͼ120 g/ml for AMK, and 40 g/ml for CAP (Table 5) .
The rrs C1402T and G1484T mutations were also analyzed in all three genetic backgrounds. In agreement with the resistance patterns detected for clinical isolates (Table 2) , engineered strains harboring the C1402T mutation were found resistant to KAN and CAP but susceptible to AMK regardless of parental genetic background (Table 4) . Similarly, all G1484T engineered mutants were completely cross-resistant to all three injectable drugs ( Table 4 ). The M. tuberculosis laboratory strain H37Rv with a C1402T mu- tation displayed a lower MIC for KAN (10 g/ml versus 15 g/ml) and AMK (2 g/ml versus 4 g/ml) compared to the CDC1551 and Beijing F2 strains but was equally resistant to CAP (80 g/ml [ Table 5 ]). All three genetic backgrounds harboring a G1484T allele were highly resistant to all drugs. Each strain displayed AMK MICs of 80 g/ml. The KAN MICs varied slightly between strains, while H37Rv exhibited the lowest MIC of 80 g/ml, followed by Beijing F2 at 120 g/ml, and CDC1551 at 160 g/ml (Table 5) . Both H37Rv and CDC1551 had CAP MICs above the highest concentration tested (Ͼ320 g/ml). Beijing F2 exhibited a slightly lower MIC of 160 g/ml (Table 5) . Effects of rrs mutations on M. tuberculosis growth. The acquisition of antibiotic-resistant mutations can result in a fitness cost; thus, when mycobacteria are exposed to drugs, mutations that provide a balance between fitness gained and lost are selected (23) (24) (25) . Previous work investigating Mycobacterium smegmatis strains expressing either WT or mutant rrs RNA found that while both the C1402T and G1484T mutations conferred significant growth disadvantages, the A1401G mutation had little effect (23) . Similarly, we used the WT parental and rrs mutant engineered M. tuberculosis strains to demonstrate that in all three genetic backgrounds, the A1401G mutation has little to no effect on growth in vitro (Fig. 1) . Conversely, the C1402T mutation had the most significant effect and increased the doubling time by 21% for the H37Rv and CDC1551 backgrounds and 34% for the Beijing F2 background (Fig. 1) . The G1484T mutation was well tolerated by H37Rv and CDC1551 strains and did not slow their growth in vitro. However, the G1484T mutation conveys a slight growth disadvantage that is more pronounced in the Beijing F2 background with reduced growth similar to that for the C1402T mutation (Fig. 1) . These apparent differences in fitness could partly explain the much higher prevalence of the A1401G mutation in clinical isolates relative to the C1402T and G1484T mutations.
DISCUSSION
Rapid molecular tests that detect the rrs A1401G mutation are currently used to predict cross-resistance patterns of the injectable antibiotics and aid in the classification of patients as either pre-XDR or XDR (3, 19, 26, 27 ). However, a major setback to adopting A1401G as a molecular marker of resistance is the wide range of CAP MICs observed in isolates with this rrs mutation. The discordance between the rrs A1401G mutation and phenotypic CAP resistance with agar proportion DST is recognized in numerous reports and ranges from 0% to 44% (3, 9, 14, 15, 17, 28) . Notably, in the limited studies examining CAP resistance using the MGIT960 system, the level of discordance associated with the A1401G mutation does appear to be reduced in comparison to agar proportion (17, 18) . However, the two methods have not been compared systematically using a large set of genetically diverse isolates. The variation in CAP MICs observed in clinical isolates harboring the M. tuberculosis rrs A1401G mutation indicates that additional factors contribute to the resistance level. Here, by using recombineering to investigate resistance levels in isogenic strains of M. tuberculosis, our data suggest that a possible explanation for this variation in clinical isolates could be due to the presence of compensatory or second-site mutations in clinical isolates.
Mycobacteriophage-based recombineering technology provides an efficient method for constructing point mutations directly in the mycobacterial genome (22, 29) and is a powerful tool for identifying the contribution of a specific mutation to drug resistance without any prior exposure to the drug and in the absence of additional confounding mutations. Using this method to introduce specific rrs mutations into three different genetic backgrounds, we found that isogenic strains of M. tuberculosis engineered to harbor the rrs A1401G mutation all had the same CAP MIC (40 g/ml [ Table 5 ]). As none of the recombineered rrs mutants had been previously exposed to any of the injectable drugs prior to MIC analysis, this level of CAP resistance is likely the amount contributed by the rrs A1401G mutation when no compensatory mutations are present. Interestingly, these results dras- tically differ from the range of CAP MICs observed in rrs A1401G mutant clinical isolates, suggesting that in many clinical isolates, the A1401G mutation alone may not be the only determining factor of CAP resistance levels. Instead, these data suggest that disparities in CAP resistance levels may be due to second-site mutations located elsewhere on the chromosome (21, 30) . Identifying the second-site mutations that influence resistance could be instructive about the mechanisms behind the variable CAP resistance levels. Alternatively, it is possible that epigenetic differences between laboratory-grown strains and clinical isolates that have been exposed to various host factors could contribute to the variability in CAP resistance levels, although it is unclear whether these types of mechanisms influence drug resistance levels in M. tuberculosis (31) . Future studies could also assist in our understanding of the mechanisms that drive the development of drug resistance.
The isogenic M. tuberculosis strains also allowed us to assess whether the genetic background of an isolate can influence resistance levels to the injectable antibiotics. The MICs to CAP, AMK, and KAN in engineered strains with rrs mutations other than A1401G varied slightly across the different lineages tested, suggesting that the combination of the genetic background of an isolate and the specific rrs mutation present can affect the level of resistance to injectable antibiotics. Although the variation in CAP MICs among clinical isolates belonging to the Beijing lineage was larger than the variation in the Euro-American lineage, our sample size of Euro-American isolates was limited, making it unclear whether this trend would hold true in a larger subset of strains. A similar phenomenon has been observed for INH resistance in clinical isolates with inhA promoter mutations, where the resistance level was shown to be a function of both the mutation and the genetic background of the isolate (21) .
The A1401G mutation is by far the most common rrs mutation associated with cross-resistance among the second-line injectable antibiotics KAN, AMK, and CAP (9) . Numerous reports of discordance between the genotypic results (i.e., A1401G mutation) and phenotypic CAP results call into question the validity of the A1401G mutation as an accurate predictor of CAP resistance (3, 14, 15, 29) . However, the A1401G mutation does appear to be a good predictor for KAN and AMK cross-resistance (8, 14, 18, 26, 27) . This molecular marker is currently used in at least one commercially available molecular test (4), and additional rapid diagnostic assays using this mutation are being developed (4, 19, 27) . As demonstrated in this report, the antibiotic concentration used to determine CAP resistance (10 g/ml) is greater than the lower range of CAP resistance in some clinical isolates, including those harboring A1401G mutations. We identified 8 clinical isolates out of 53 with an A1401G mutation that had MICs just below the recommended testing concentration of 10 g/ml. Therefore, discordance between molecular detection of CAP resistance and growth-based DST could be due primarily to borderline resistant isolates. Notably, these A1401G mutants would be characterized as resistant using molecular methods to detect drug resistance such as sequencing, real-time PCR, or hybridization-based assays (3, 4, 19, 27) .
The concept of reducing the critical concentration for determination of CAP resistance has been suggested in previous studies (15, 17, 20) , and in 2012, the Global Laboratory Initiative (GLI) Working Group discussed the possibility of lowering the critical concentration to 4 g/ml for agar proportion DST on 7H10 medium. This recommendation was published online recently (http://www.stoptb.org/wg/gli/assets/documents/Updated %20critical%20concentration%20table_1st%20and%202nd %20line%20drugs.pdf), and if it were adopted by the scientific community, the detection of these borderline resistant strains could ultimately strengthen the predictive correlation between the A1401G mutation and phenotypic CAP resistance. If the clinical isolates in this study were reanalyzed using a CAP critical concentration of 4 g/ml, all isolates harboring A1401G mutations would have been classified as CAP resistant, and as important, all of the pansusceptible isolates would test susceptible at this lower concentration. However, many of the pansusceptible isolates exhibited an MIC of 4 g/ml, which is equal to the critical concentration, and we need to monitor the rate of false resistance using this lower concentration and possibly reevaluate this level at a later time once enough data have been generated. Similarly, if other studies were retroactively analyzed at this reduced critical concentration, we predict that most of the discordance would be eliminated, and the positive predictive values for determining CAP resistance would be vastly improved.
Additionally, we identified two clinical isolates in this study containing WT rrs genotypes that exhibit CAP MICs of 8 g/ml (Table 3) , and thus, would be considered CAP susceptible by current standards. However, because our data provide strong evidence that the intrinsic resistance level of several lineages of M. tuberculosis to CAP is below 4 g/ml (Tables 3 and 5) , it also suggests that a CAP MIC of 8 g/ml (Table 3) in WT rrs strains is not due to breakthrough resistance but rather could be due to a previously unidentified mechanism of CAP resistance. By lowering the critical concentration of CAP, borderline CAP-resistant strains like these two clinical isolates would still be detected by agar-based DST, even though they lack known molecular markers of CAP resistance.
In conclusion, the documented discordant relationship between phenotypic CAP resistance and the rrs A1401G mutation has prevented this mutation from being considered a strong predictor of CAP resistance. Here, we present data that a major factor in this discordance is that clinical isolates harboring an A1401G mutation exhibit variable resistance levels to CAP (with MICs ranging from 8 to 40 g/ml [ Table 3 ]) with some falling below the currently used standard for determining CAP resistance. Our data corroborate the results of other reports that have suggested that lowering the critical concentration of CAP would more accurately determine the resistance pattern in clinical isolates.
